Nothing Special   »   [go: up one dir, main page]

DE60026514D1 - Neue prolinverbindungen als mikrobizide mittel - Google Patents

Neue prolinverbindungen als mikrobizide mittel

Info

Publication number
DE60026514D1
DE60026514D1 DE60026514T DE60026514T DE60026514D1 DE 60026514 D1 DE60026514 D1 DE 60026514D1 DE 60026514 T DE60026514 T DE 60026514T DE 60026514 T DE60026514 T DE 60026514T DE 60026514 D1 DE60026514 D1 DE 60026514D1
Authority
DE
Germany
Prior art keywords
prolin
microbicide
compounds
medium
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60026514T
Other languages
English (en)
Other versions
DE60026514T2 (de
Inventor
Aaron H Leeman
Milton L Hammond
Milana Maletic
Gina M Santorelli
Sherman F Waddell
John Finn
Michael Morytko
Siya Ram
Dennis Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Cubist Pharmaceuticals LLC
Original Assignee
Merck and Co Inc
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc, Cubist Pharmaceuticals LLC filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60026514D1 publication Critical patent/DE60026514D1/de
Publication of DE60026514T2 publication Critical patent/DE60026514T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
DE60026514T 1999-05-05 2000-05-05 Neue prolinverbindungen als mikrobizide mittel Expired - Fee Related DE60026514T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13254699P 1999-05-05 1999-05-05
US132546P 1999-05-05
PCT/US2000/012172 WO2000066119A1 (en) 1999-05-05 2000-05-05 Novel prolines as antimicrobial agents

Publications (2)

Publication Number Publication Date
DE60026514D1 true DE60026514D1 (de) 2006-05-04
DE60026514T2 DE60026514T2 (de) 2006-11-09

Family

ID=22454536

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026514T Expired - Fee Related DE60026514T2 (de) 1999-05-05 2000-05-05 Neue prolinverbindungen als mikrobizide mittel

Country Status (9)

Country Link
US (3) US6333344B1 (de)
EP (1) EP1176959B1 (de)
JP (1) JP2002543129A (de)
AT (1) ATE319446T1 (de)
AU (1) AU769652B2 (de)
CA (1) CA2372176A1 (de)
DE (1) DE60026514T2 (de)
ES (1) ES2257296T3 (de)
WO (1) WO2000066119A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120661T2 (de) * 2000-03-27 2007-07-05 Applied Research Systems Ars Holding N.V. Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren
EA006424B1 (ru) * 2000-03-27 2005-12-29 Апплайд Резеч Системз Арс Холдинг Н.В. Фармацевтически активные производные пирролидина
RU2290403C2 (ru) * 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
PL367275A1 (en) 2001-06-18 2005-02-21 Applied Research Systems Ars Holding N.V. Pyrrolidine oxadiazole- and thiadiazole derivatives
CN1298321C (zh) * 2002-04-19 2007-02-07 亚利桑那大学董事会 光损伤调控物在制备用于抑制由紫外线引起的光损伤的药物中的用途
WO2005009336A2 (en) * 2003-05-01 2005-02-03 Replidyne, Inc. Antibacterial methods and compositions
WO2005009992A1 (ja) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. シクロヘキサンカルボン酸類
JP2006143667A (ja) * 2004-11-22 2006-06-08 Ube Ind Ltd ピペコリン酸アミド誘導体及び抗菌剤
CA2606804A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
EP3608317A1 (de) * 2012-01-12 2020-02-12 Yale University Verbindungen und verfahren für den verstärkten abbau von gezielten proteinen und anderen polypeptiden durch eine e3-ubiquitinligase
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
KR102110566B1 (ko) 2015-01-20 2020-05-13 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
EP3302482A4 (de) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-bindende kinase-1-protacs und zugehörige verfahren zur verwendung
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
ES2945224T3 (es) 2016-10-11 2023-06-29 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
BR112019012878A2 (pt) 2016-12-23 2019-11-26 Arvinas Operations Inc compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3710443A1 (de) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Verbindungen und verfahren zum gezielten abbau von mit interleukin-1-rezeptor assoziierten kinase-4-polypeptiden
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
EP3841100A1 (de) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Gegen alpha-synnukleinprotein gerichtete proteolyse-targeting chimeräre (protac) verbindung mit e3-ubiquitin-ligase-bindender aktivität zur behandlung neurodegenerativer erkrankungen
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
JP2022546471A (ja) 2019-08-26 2022-11-04 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
PH12022551486A1 (en) 2019-12-19 2023-11-13 Arvinas Operations Inc Compounds and methods for the targeted degradation of androgen receptor
US12043612B2 (en) 2020-05-09 2024-07-23 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
EP4204418A1 (de) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Schnell beschleunigende fibrosarkomproteinabbauende verbindungen und zugehörige verfahren zur verwendung
CR20230162A (es) 2020-09-14 2023-06-02 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4812470A (en) 1982-02-27 1989-03-14 Beecham Group P.L.C. Antibacterial monic acid derivatives
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
JPH03236389A (ja) * 1990-02-13 1991-10-22 Banyu Pharmaceut Co Ltd 2―(2―カルバモイルピロリジニルチオ)カルバペネム誘導体
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JPH09504512A (ja) 1993-08-13 1997-05-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌活性、抗マイコプラズマ活性、抗真菌類活性および除草活性を有するモン酸aおよびcの誘導体
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
WO1996002534A1 (de) * 1994-07-20 1996-02-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5726195A (en) 1995-07-28 1998-03-10 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU7084996A (en) * 1995-09-15 1997-04-01 Smithkline Beecham Plc Pyrrolidine and thiazole derivatives with antibacterial and metallo-beta-lactamase inhibitory properties

Also Published As

Publication number Publication date
DE60026514T2 (de) 2006-11-09
US6333344B1 (en) 2001-12-25
US20030013724A1 (en) 2003-01-16
EP1176959A4 (de) 2002-10-09
EP1176959A1 (de) 2002-02-06
JP2002543129A (ja) 2002-12-17
AU4984500A (en) 2000-11-17
EP1176959B1 (de) 2006-03-08
ES2257296T3 (es) 2006-08-01
US6417217B1 (en) 2002-07-09
ATE319446T1 (de) 2006-03-15
AU769652B2 (en) 2004-01-29
CA2372176A1 (en) 2000-11-09
US6579894B2 (en) 2003-06-17
WO2000066119A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
DE60026514D1 (de) Neue prolinverbindungen als mikrobizide mittel
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
LU92824I2 (fr) Ceritinib ou un sel pharmaceutiquement acceptable de celui-ci
WO2002094794A8 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
BG107195A (en) AMIDE COMPOUND AND ITS APPLICATION AS Rho KINASE INHIBITOR
ATE241617T1 (de) Pyrimidinverbindungen
CA2341890A1 (en) Oxygen-containing heterocyclic compounds
YU44998A (sh) Pirazolska jedinjenja, postupci za njihovu proizvodnju i herbicidi koji ih sadrže
ATE259376T1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
EE05035B1 (et) 1-[fenüül-(8-kinolinüül)metüül]piperasiini derivaadid ning nende kasutamine meditsiinis
MXPA03010443A (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o trastornos gastrointestinales.
DE60201921D1 (de) Kondensierte Pyrazolverbindungen
CA2409842A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
RS50109B (sr) Derivati 4-heterociklilsulfonamidil-6-metoksi-5-(2-metoksi- fenoksi)-2-piridil-piridimina, njihovo dobivanje i primena kao antagonisti endotelinskih receptora
BR0213176A (pt) Derivados microbiocidas de n-fenil-n-[4-(4-piridil)-2-pirimidin-2-il]amina
FI935798A0 (fi) Alkylsubstituerade heterocykliska foereningar
MEP17408A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
BG106784A (en) 3-(4,5-dihydroisoxalole-5-yl)benzoylpyrazole
CA2170637A1 (en) Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
EP0721930A4 (de) Benzoethylenderivat
MXPA03010442A (es) Derivados de 4-(fenil-(piperidin-4-il)-amino)-benzamida y sus usos para tratamiento de dolor, ansiedad o desordenes gastrointestinales.
YU78001A (sh) Derivati 6-(((aril i heteroaril)oksi)metil) naftalen-2- karboksimidamida, njihovo dobijanje i terapeutska primena
SE0101769D0 (sv) Novel compounds
SE0101770D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO, INC., RAHWAY, N.J., US

Owner name: CUBIST PHARMACEUTICALS, INC., LEXINGTON, MASS., US

8339 Ceased/non-payment of the annual fee